

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

ANALYSIS, REPORTING & MANAGEMENT of URINARY HUMAN CHORIONIC GONADOTROPHIN (hCG) and LUTEINIZING HORMONE (LH) FINDINGS IN MALE ATHLETES

The purpose of this *Technical Document (TD)* is to ensure a harmonized approach in the reporting and management of elevated urinary concentrations of human Chorionic Gonadotrophin (hCG) and Luteinizing Hormone (LH).

The finding of the α/β heterodimer of hCG in the urine of male *Athletes* at concentrations greater than the established *Decision Limit (DL)* may be an indicator of hCG *Use* for doping purposes. However, due to the association of elevated urinary hCG with pathology, such as testicular cancer, consideration must be given to possible causes, other than doping, which can produce elevated concentrations of heterodimeric hCG in urine *Samples* from male *Athletes*.

[Comment: The α/β heterodimer of hCG includes the intact α/β heterodimer as well as the ‘nicked’ α/β heterodimer, in which the β -subunit is (usually) cleaved between residues 47 and 48. Although cleaved, the α and β -subunits in the nicked hCG are held together by non-covalent bonds.

Immunoassays developed against ‘intact hCG’ typically measure these two forms of the α/β heterodimeric hCG molecule. In contrast, assays for ‘total hCG’ measure other molecular forms of hCG (e.g. α - and β - subunits or degradation fragments such as the β -core fragment) in addition to the α/β heterodimer.]

Elevated concentrations of total LH in urine of male *Athletes* may also be an indication of the administration of this *Prohibited Substance* for doping purposes or of the *Use* of other *Prohibited Substances* that induce the release of endogenous LH, such as gonadotropin-releasing factors (*i.e.* gonadotropin-releasing hormone (GnRH) and its synthetic analogs) or estrogen blockers (anti-estrogens, aromatase inhibitors). On the other hand, suppressed urinary concentrations of LH in male *Athletes* may be an indication of, or corroborative finding for, the *Use* of androgens.

[Comment: Total LH includes the α/β LH heterodimer as well as the dissociated β -subunit and their degradation products.]

The objective of this *TD* is to assist Laboratories with reporting analytical findings for hCG and LH and aid *Anti-Doping Organizations (ADOs)* to determine whether an anti-doping rule violation (ADRV) has occurred.

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

1.0 Introduction

- hCG and LH are prohibited in male *Athletes* only;
- hCG and LH are both heterodimeric proteins comprising two (2) polypeptide chains, a common α -subunit and a unique β -subunit (hCG β , LH β). Only the α/β heterodimer has biological activity, which is determined by the hormone-specific β -subunit;
- Both hCG and LH occur in urine in different molecular forms, including the intact and nicked α/β heterodimers as well as the dissociated α - and β -subunits and their degradation products (e.g. the β -core fragments, nicked products, etc.);
- In men, hCG and LH stimulate production of testosterone by Leydig cells by binding to and activating CG/LH receptors;
- The heterodimeric hCG is either undetectable or found at very low levels (usually below 2 IU/L) in urine from healthy, non-doping males. However, elevated levels of heterodimeric hCG, free hCG β , hCG β -core fragment are produced by certain malignant tumors, especially in cases of testicular cancer. Heterodimeric hCG may also be produced by extra-testicular germ cell tumors. In addition, hCG β may be produced by various non-trophoblastic cancers;
- Endogenous LH is normally detectable in urine from healthy men. LH has a shorter half-time in circulation than hCG. Circulating LH is subject to negative feedback by the production of endogenous testosterone or the administration of androgens.

2.0 Pre-analytical Procedure

- Before aliquoting for analysis, the urine *Sample* should be homogenized in the *Sample* bottle;
- Aliquots taken for analysis should be analyzed immediately. However, if necessary, Aliquots may be stored refrigerated for up to seven (7) days until analysis. Aliquots should not be frozen;
- If stored refrigerated, Aliquots should be re-suspended after removal from storage (e.g. by pipetting, vortexing or shaking). Aliquots should be allowed to reach room temperature before being loaded into the instrument for analysis;
- In case of a Presumptive Adverse Analytical Finding (PAAF), “A” *Samples* stored at -20 °C should be subjected to the Confirmation Procedure (CP) as soon as possible;

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

- “B” Samples associated with an *Adverse Analytical Finding (AAF)* for hCG in the “A” Sample should be subjected to the CP or transferred to deep freezing storage (-70 °C or less) as soon as possible until analysis.

3.0 Analytical Testing Strategy

3.1 Analytical Testing for hCG

3.1.1 Initial Testing Procedure (ITP)

- For the ITP, assays (immunoassays, chromatographic-mass spectrometric assays ^[1]), which are specific for either the α/β heterodimer of hCG or for ‘total hCG’ may be used;

[Comment: Men with “familial hCG”, an apparently physiological and non-pathological anomaly of hCG secretion, have consistently elevated concentrations of hCG β in serum and urine. This may cause a positive finding if an assay for “total” hCG is used. Therefore, the Laboratory may also consider measuring total hCG only as an initial pre-screening procedure for practical reasons (e.g. the lack of an automated assay for heterodimeric hCG), and subsequently subjecting any Sample with a suspicious result (> 5.00 IU/L) to an ITP using an assay specific for heterodimeric hCG].

- The Laboratory shall use at least one quality control (QC) sample at levels close to 5 IU/L (immunoassays) or 2 IU/L (chromatographic-mass spectrometric assays). The consistency of the hCG measurements of the QC shall be monitored through the use of QC-charts.

[Comment: It is recommended that the QC samples be prepared in the matrix of analysis (urine), aliquoted and stored deep frozen (-70 °C or less) until use.]

3.1.2 Confirmation Procedure (CP)

- For the CP(s), Laboratories shall apply an assay validated to be as Fit-for-Purpose to detect and quantify specifically the α/β heterodimer of hCG (immunoassay or chromatographic-mass spectrometric assay ^[1]). The same assay (immunoassay or LC-MS/MS assay) shall be used for both the “A” and the “B” Sample CP;

[Comment: Fit-for-Purpose immunoassays for quantification of hCG α/β heterodimer in urine include, for example, the Roche hCG STAT, DELFIA and the Siemens EXL Dimension assays. Nevertheless, the Laboratory shall validate the assay and have it incorporated within its Scope of ISO/IEC 17025 Accreditation before application to the analysis of Samples.]

- The acceptance values for the parameters of α/β heterodimeric hCG assay performance, as determined during CP Test Method validation, are specified in the table below:

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA Laboratory Expert Group		
Date:	21 December 2020	Effective Date:	1 April 2021

Validation Parameter	Acceptance Criterion	
	Immunoassays	LC-MS/MS
s_r (Repeatability)	≤ 10 % (at 5.00 IU/L)	≤ 10 % (at 2.00 IU/L)
s_w (Intermediate Precision)	≤ 15 % (at 5.00 IU/L)	≤ 15 % (at 2.00 IU/L)
LOQ * (Limit of Quantification)	≤ 3.00 IU/L	≤ 0.50 IU/L
u_{c_Max} (%) (Maximum Combined Standard Uncertainty)	20 % (at 5.00 IU/L)	20 % (at 2.00 IU/L)

* **LOQ** is defined as the lowest hCG concentration in urine meeting the specified criteria for u_{c_Max} .

- If the Laboratory uses an immunoassay specific for total hCG for the ITP, then an assay specific for the α/β heterodimer of hCG (LC-MS/MS or an immunoassay) shall be used for the CP(s);
- If the Laboratory uses immunoassays specific for the α/β heterodimer of hCG for both the ITP and the CP(s), then the confirmation immunoassay shall be different from the immunoassay applied for the ITP;
- If the Laboratory uses an LC-MS/MS-based assay specific for the α/β heterodimer of hCG for the ITP, then the same LC-MS/MS-based assay or an immunoassay (also specific for the α/β heterodimer of hCG) may be used for the CP(s);
- Laboratories that do not have the analytical capacity to perform the CP(s) for hCG with a (second) immunoassay specific for the α/β heterodimer of hCG or with an LC-MS/MS assay shall have, upon consultation with the responsible Testing Authority, the *Sample* shipped to and analyzed by another Laboratory that has such analytical capacity;

[Comment: A second immunoassay specific for the α/β heterodimer of hCG is needed for the CP(s) only if the Laboratory uses an immunoassay specific for the α/β heterodimer of hCG for the ITP and it does not have a validated LC-MS/MS assay.]

[Comment: For further guidance, refer to the WADA Guidelines on Conducting and Reporting Subcontracted Analysis and Further Analysis for Doping Control].

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

- The Laboratory shall use a negative (concentration less than (<) the corresponding *DL*) and a positive (6 - 15 IU/L) urine QC sample. The consistency of the hCG measurements of the QCP shall be monitored through the use of QC-charts;
- For *Samples* producing a PAAF for hCG (α/β heterodimer or ‘total’ hCG, as applicable), the “A” *Sample CP* should be performed as soon as possible. Alternatively, the remainder of the “A” *Sample* and the “B” *Sample* should be deep frozen (at -70 °C or less) immediately until analysis;
- For both “A” and “B” CP, three (3) *Sample Aliquots* shall be measured, except when there is limited *Sample* volume, in which case a lower maximum number of replicates may be used.

3.2 Analytical Testing for LH

3.2.1 Initial Testing Procedure (ITP)

- Laboratories should determine the concentrations of total LH in urine during the ITP by applying an assay for **total LH**, which is capable of measuring the total content of LH immunoreactivity, *i.e.* capable of detecting the α/β heterodimer as well as the free β -chain and the β -core fragment (*e.g.* Siemens Immulite, DELFIA);
- The Laboratory shall use at least one QC sample with total LH concentration between 5 – 50 IU/L. The consistency of the total LH measurements of the QC shall be monitored through the use of QC-charts.

[Comment: It is recommended that the QC samples be prepared in the matrix of analysis (urine), aliquoted and stored deep frozen (-70 °C or less) until use.]

3.2.2 Confirmation Procedure (CP)

- If the ITP produces a PAAF for LH, the Laboratory shall test the *Sample* for the presence of gonadotropin-releasing factors (*e.g.* buserelin, gonadorelin, leuprorelin), anti-estrogenic substances and aromatase inhibitors.

[Comment: Analysis for anti-estrogenic substances and aromatase inhibitors shall be part of the Laboratory’s standard Analytical Testing menu. Analysis for gonadotropin-releasing factors may not be part of the Laboratory’s routine Analytical Testing menu; however, Laboratories shall have analytical capacity to apply this method as a CP for elevated LH findings.]

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

4.0 Interpretation and Reporting of Results

4.1 hCG results

4.1.1 ITP Results

i. Presumptive Adverse Analytical Finding (PAAF)

- The ITP will produce a PAAF for hCG, if the concentration of hCG (either the hCG- α/β heterodimer or ‘total’ hCG) in the *Sample* is greater than (>) 5.00 IU/L for immunoassays, or greater than (>) 2.00 IU/L for LC-MS/MS assays.

[Comment: In accordance with the International Standard for Laboratories (ISL)^[2], when there is a PAAF for hCG, the Laboratory may contact the Testing Authority (or Results Management Authority, if different), in writing, to enquire whether an approved Therapeutic Use Exemption (TUE) exists for hCG. The Laboratory should provide the hCG concentration determined from the ITP. However, this is not a mandatory requirement for the Laboratory; the Laboratory may proceed, at its discretion, to confirm the PAAF.

The instruction by the Testing Authority (or Results Management Authority, if different) on whether the Laboratory shall proceed or not with the confirmation based on an approved TUE shall be provided to the Laboratory in writing. If not proceeding with the confirmation, then the Testing Authority (or Results Management Authority, if different) shall provide WADA with a copy of the approved TUE or the associated TUE number if the TUE has been submitted into ADAMS.]

ii. Negative Finding

- The Laboratory should consider the result for hCG as a Negative Finding when the ITP produces a result for the hCG- α/β heterodimer or ‘total hCG’, as applicable, which is less than or equal to (\leq) 5.00 IU/L for immunoassays, or less than or equal to (\leq) 2.00 IU/L for LC-MS/MS assays.

[Comment: The Laboratory should report these results as Negative Findings unless the Laboratory, based on ITP method validation data, concludes that the result should be considered as a PAAF and subjected to a CP].

4.1.2 CP Results

i. Adverse Analytical Finding (AAF)

- The Laboratory shall report an AAF for hCG if the CP confirms the presence of the hCG- α/β heterodimer at concentrations greater than (>) the DL of 5.00 IU/L (immunoassays) or 2.00 IU/L (LC-MS/MS).
- For urine *Samples* with measured values of specific gravity (SG_{Sample}) greater than (>) 1.018, the DL shall be adjusted.

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

[Comment: For urine Samples with $SG_{Sample} > 1.018$, the DL for hCG shall be adjusted according to Eq. 1:

$$(Eq. 1) \quad DL_{adj} = \frac{(SG_{Sample_Max} - 1)}{(LO20 - 1)} \cdot DL$$

where $DL = 5.00$ IU/L for immunoassays and 2.00 IU/L for LC-MS/MS.

Refer to the effective TD DL ^[3] for instructions on calculating SG_{Sample_Max} .

The DL_{adj} shall be expressed truncated to three significant figures (e.g. a DL_{adj} of 5.326 shall be expressed as 5.32; trailing zeros (0) shall be considered as significant figures, e.g. 5.30; 6.00).]

- When reporting an AAF for hCG, the Laboratory Test Report shall include the mean concentration of the hCG- α/β heterodimer (expressed in international units per litre (IU/L) truncated to three (3) significant figures) of the replicate determinations performed during the CP as well as the relative combined standard uncertainty u_c (%) at values close to the DL as determined by the Laboratory during method validation;
- In case of an AAF for hCG, a comment shall be added to the Test Report recommending the ADO to advise the *Athlete* to undergo clinical investigations to exclude any pathological cause for the elevated urinary hCG (see Annex 1).

ii. Negative Finding

- The Laboratory shall report the confirmation result for hCG as a Negative Finding when the CP produces a result for the hCG- α/β heterodimer, which is less than or equal to (\leq) 5.00 IU/L for immunoassays, or less than or equal to (\leq) 2.00 IU/L for LC-MS/MS assays, or less than or equal to (\leq) the adjusted DL value if the $SG > 1.018$;
- A CP Negative Finding for the hCG- α/β heterodimer is associated with a PAAF from the ITP for either 'total hCG' or intact hCG, as applicable. Therefore, in these cases the Laboratory shall also make a comment on the Test Report recommending the ADO to advise the *Athlete* to undergo clinical investigations to exclude any pathological cause for the elevated urinary hCG (see Annex 1).

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

4.2 LH results

For urine *Samples* with $SG_{Sample} > 1.018$, LH concentrations shall be adjusted to $SG = 1.020$.

[Comment: For urine Samples with values of $SG_{Sample} > 1.018$, the LH concentration in the Sample shall be adjusted according to Eq. 2:

$$(Eq. 2) \quad Conc_{adj} = \frac{(1.020 - 1)}{(SG_{Sample_Max} - 1)} \cdot Conc_{measured}$$

Refer to the effective TD DL ^[3] for instructions on calculating SG_{Sample_Max}].

4.2.1 ITP Results

i. Presumptive Adverse Analytical Finding (PAAF)

- The Laboratory shall conclude a PAAF for LH when the measured concentration of total LH in the ITP (after adjustment if urine $SG > 1.018$) is greater than ($>$) 60.0 IU/L when using the Immulite assay or greater than ($>$) 40.0 IU/L when applying the DELFIA assay;
- The Laboratory shall report in *ADAMS* the measured concentration of total LH, expressed truncated to three (3) significant figures (trailing zeros (0) shall be considered as significant figures, e.g. 45.0; 110).

ii. Negative Finding

- The Laboratory should consider the result for LH as a Negative Finding when the measured concentration of total LH in the ITP (after adjustment if urine $SG > 1.018$) is less than or equal to (\leq) 60.0 IU/L when using the Immulite assay or less than or equal to (\leq) 40.0 IU/L when applying the DELFIA assay;
- In cases when LH is not detectable in the *Sample*, the Laboratory shall report in *ADAMS* that “the concentration of LH was less than the Limit of Detection (LOD)” and specify the applicable LOD.

4.2.2 CP Results

i. Adverse Analytical Finding (AAF)

- When there is a PAAF for LH, and tests are performed to detect the presence of gonadotropin-releasing factors, anti-estrogenic substances and aromatase inhibitors, the Laboratory shall report an AAF if any one of these *Prohibited Substances* is confirmed in the *Sample* (in accordance with the TD IDCR ^[4]). In addition, the Laboratory shall report the estimated concentration of LH (expressed truncated to three (3) significant figures).

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

ii. Atypical Finding (ATF)

- When there is a PAAF for LH, and tests performed to detect the presence of gonadotropin-releasing factors, anti-estrogenic substances and aromatase inhibitors produce negative results, the Laboratory shall report the *Sample* as an ATF. The Laboratory shall report the estimated concentration of LH (expressed truncated to three (3) significant figures).

5.0 Results Management

5.1 hCG findings

- When a *Sample* is reported as an AAF for hCG or as a Negative Finding for a non-confirmed PAAF for intact or total hCG, as applicable (*i.e.* an initial PAAF for ‘total’ or ‘intact’ hCG is followed by a negative confirmation result for ‘intact’ hCG), the ADO should alert the *Athlete* and advise that clinical investigations be performed within a reasonable time frame to exclude pathological causes of the elevated urinary hCG concentrations (see Annex 1). **No Provisional Suspension shall be imposed on the Athlete for the AAF during the course of the clinical investigations.** The ADO should advise WADA when clinical investigations are conducted on an *Athlete*;

[Comment: Cases of a non-confirmed PAAF for α/β heterodimeric (‘intact’) or ‘total’ hCG may be caused by hCG degradation in urine following Sample collection. However, a non-confirmed PAAF for ‘total’ hCG may also be related to a pathological cause, since most cases of testicular cancer are associated with elevated free hCG β and hCG β -core fragment in urine.]

An AAF or non-confirmed PAAF for the α/β heterodimeric hCG does not exclude either the possibility of a pathological cause, since testicular cancer is also linked to elevated serum and urine concentrations of heterodimeric hCG. In such cases, it is a responsibility of the Athlete to provide medical information or clinical evidence demonstrating that the AAF for heterodimeric hCG is the result of a pathological condition.]

- When a *Sample* is reported as an AAF or a confirmed Negative Finding for hCG (associated with a PAAF for intact or total hCG, as applicable), it is recommended that the ADO conducts at least one (1) follow-up no-notice test within a reasonable time frame (*e.g.* within 2 weeks) following the initial finding. If possible, the follow-up *Sample* should be analyzed at the same Laboratory and using the same assays that produced the initial finding. If a different Laboratory is to be used, at least the same confirmatory assay for hCG shall be applied;
- If no clinical evidence is provided or the clinical investigations determine that there is no pathological condition associated with the AAF, the results management process is followed as in the case for *Use of other Prohibited Substance(s) or Prohibited Method(s)*. The results of

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

the follow-up *Sample(s)* should be considered when evaluating the initial findings and the clinical information;

[Comment: For example, a negative result for the follow up Sample is more consistent with prior Use of hCG and the absence of a pathological condition.]

- If medical information is provided by the *Athlete* to support the claim that the *AAF* is due to a physiological or pathological condition, such information shall be taken in to account and should lead the *ADO* to stop the result management process of the case as an *ADRV*.

5.2 LH findings

- If the presence of gonadotropin-releasing factors, anti-estrogenic substances or aromatase inhibitors is reported as an *AAF*, the results management process is followed, as in the case for *Use of any other Prohibited Substance(s) or Prohibited Method(s)*;
- If an *ATF* for LH is reported (elevated total LH concentration with negative results for gonadotropin-releasing factors, anti-estrogens and aromatase inhibitors), the *ADO* should conduct at least one (1) follow-up no-notice test on the *Athlete* within a reasonable time frame (e.g. within 2 weeks) following the initial finding, unless the *ADO* has longitudinal data for the *Athlete* that indicates a follow-up is not warranted;
- The follow-up *Sample* should be preferably analyzed at a Laboratory that applies the same assay for total LH as the one used on the first *Sample*;
- The *ADO* should consider the results of longitudinal tests for LH in parallel with the evaluation of the longitudinal “steroid profile” of the *Athlete*. This evaluation should be done in consultation with an Athlete Passport Management Unit (APMU).

6.0 References

- [1] Woldemariam GA and AW Butch. Immunoextraction-Tandem Mass Spectrometry Method for Measuring Intact Human Chorionic Gonadotropin, Free β -Subunit, and β -Subunit Core Fragment in Urine. *Clin Chem* **60**: 1089-1097, 2014.
- [2] The World Anti-Doping *Code International Standard for Laboratories (ISL)*.
- [3] *WADA Technical Document TD DL. Decision Limits for the Confirmatory Quantification of Exogenous Threshold Substances by Chromatography-based Analytical Methods*.
- [4] *WADA Technical Document TD IDCR. Minimum Criteria for Chromatographic-Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes*.

[Current versions of the WADA ISL and Technical Documents may be found at <https://www.wada-ama.org/en/what-we-do/science-medical/laboratories>]

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

Annex 1.

Medical Evaluation of a Case with Confirmed Positive hCG Test

An *Adverse Analytical Finding (AAF)* for hCG in a male *Athlete* should lead to investigation of a pathological, non-doping cause before charging the *Athlete* with an anti-doping rule violation (ADRV) for hCG doping. (Note: hCG is not prohibited in female *Athletes*). Such a medical assessment to determine a possible pathology shall also be conducted in cases of non-confirmed Presumptive Adverse Analytical Findings (PAAF) (*i.e.* an initial PAAF for ‘total’ or ‘intact’ hCG is followed by a negative confirmation result for ‘intact’ hCG).

1.0 Testing for hCG

hCG is a heterodimeric glycoprotein comprised of two subunits, α (hCG α) and β (hCG β). hCG occurs in urine in different molecular forms, including the intact and nicked α/β heterodimers as well as the dissociated α - and β -subunits and their degradation products (*e.g.* the β -core fragments, nicked products, etc.).

Both hCG, its subunits and their fragments may be detected in urine by hCG immunoassays with wide specificity (“total hCG” assays). Anti-doping tests, however, aim to confirm the presence and quantify only the hCG- α/β heterodimer (*i.e.* by applying so-called “intact hCG” assays for Confirmation Procedures, which in addition to the intact α/β heterodimer may also detect the “nicked” α/β heterodimer).

The heterodimeric hCG is either undetectable or found at very low levels (usually below 2 IU/L) in urine from healthy males. However, heterodimeric hCG may be produced by testicular cancers or extra-testicular germ cell tumors. If such tumors can be excluded, the otherwise unexplained presence of elevated levels of heterodimeric hCG in serum or urine is evidence for the pharmacological administration of hCG.

A positive “intact hCG” test result (*AAF*) in an *Athlete* (or a non-confirmed PAAF, *e.g.* for ‘total’ hCG) may be due to an undiagnosed testicular tumor containing trophoblastic elements that synthesize hCG. Rarely, ectopic hCG secretion can arise from extra-testicular germ cell tumors, typically located in the midline of the mediastinum, retro-peritoneum or pineal gland. These extra-testicular tumors have a significantly worse prognosis than testicular germ cell tumors.

[Comment: A non-confirmed PAAF may also be associated with doping but results from intact hCG degradation during Sample storage.]

WADA Technical Document – TD2021CG/LH

Document Number:	TD2021CG/LH	Version Number:	1.0
Written by:	WADA Science/CG/LH Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA Laboratory Expert Group		
Date:	21 December 2020	Effective Date:	1 April 2021

2.0 Medical Evaluation

Following an *AAF* or a non-confirmed *PAAF* for hCG, the first step is to promptly exclude a pathological cause by a medical assessment. The importance of this assessment should be communicated to the *Athlete* who should subsequently be reviewed by a doctor, ideally a urologist or an endocrinologist.

The medical assessment of a potential pathological cause of a positive hCG test must include:

1. History (including cryptorchidism, family history);
2. Physical examination (including testes palpation, testis volume, gynecomastia);
3. Laboratory investigations - serum hCG (intact), alpha fetoprotein (AFP), LDH as tumor marker and serum LH, FSH, testosterone, SHBG (to detect hCG bioactivity);
4. Imaging;
 - a. Ultrasound of testes (hypoechoic lesions, microlithiasis);
 - b. If serum hCG (intact) assay remains positive and there is no palpably enlarged testis or presumptive tumor identified by ultrasound, imaging to exclude an extra-testicular germ cell tumor is indicated by CT scan (alternatively MRI or PET scan) of chest, abdomen and brain.

A palpably enlarged testis requires referral to a urologist or oncologist for further evaluation and treatment of a presumed testis tumor.

If serum hCG (intact) remains elevated and no testis or extra-testicular tumor is identified in the original investigation, the *Athlete* should have a clinical follow-up with the same serum hCG (intact) immunoassay, including repeat testis ultrasound (to examine for any new or changed hypoechoic testicular lesions) after three (3) months. As some of these tumors may be slow growing, follow-up to exclude a testis tumor may need to be prolonged (up to two (2) years).

Although the investigation for testicular tumors/cancers should be pursued without delay, further anti-doping *Testing* during the period of investigation is often required to clarify the situation.